NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Enzyme Replacement Therapy Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 964971
出版日期 內容資訊 英文 117 Pages
商品交期: 2-3個工作天內
□替代療法的全球市場:增長,趨勢,預測(2020-2025) Enzyme Replacement Therapy Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 117 Pages

在預測期內,□替代療法的市場規模預計將以7.7%的複合年增長率增長。越來越多的罕見疾病負擔以及政府和其他機構為應對罕見疾病所做的努力將為市場的增長做出巨大貢獻。 2018年,歐洲藥品管理局(EMA)的人類藥物委員會(CHMP)批准了Ramzede的上市許可,Ramzede用於歐盟的Alpha甘露糖甘病的治療。根據EURORDIS的資料,目前有6,000多種罕見疾病,歐洲約有3000萬人受到該疾病的影響。此外,這些罕見疾病中至少有80%是慢性病,危及生命。因此,罕見病的治療至關重要,從而推動了□替代療法市場的增長。







  • 市場概況
  • 市場驅動力
    • 罕見病患病率上升
    • 加強政府對罕見病的倡議
  • 市場限制
    • 高昂的治療費用
  • 波特的五力分析


  • 按□的類型
    • 瓊脂糖□Alpha
    • Agalsider Zebeta
    • 甘硫□
    • 其他□類型
  • 按應用
    • 高雪氏病
    • 龐貝病
    • 法布裡氏病
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美洲


  • 公司簡介
    • Amicus Therapeutics
    • Biomarin Pharmaceutical Inc.
    • Genzyme Corporation
    • Johnson & Johnson
    • Leadiant Biosciences Inc.
    • Pfizer Inc.
    • Protalix Biotherapeutics
    • Takeda Pharmaceutical Company Limited

第7章 市場機會與動向


Product Code: 68635

The enzyme replacement therapy market is expected to register a CAGR of 7.7% during the forecast period. The increasing burden of rare diseases and the initiatives taken by the government and others for rare diseases is expected to be a key contributor in the enzyme replacement therapy market growth. In 2018, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) granted the marketing authorization for Lamzede used for treating Alpha-mannosidosis in the European Union. According to the EURORDIS, currently, there are over 6000 rare diseases in existence, and around 30 million of the population in Europe has been affected by it. Furthermore, at least 80% of these rare disorders are chronic and life-threatening. Hence, the treatment of rare diseases is of utmost importance, thereby, boosting the enzyme replacement therapy market growth.

Key Market Trends

Agalsidase Alfa Segment is Expected to Hold a Major Market Share in the Enzyme Replacement Therapy Market

Fabry is an X-linked rare disease that comes in the group of lysosomal storage disorders. Algasidase Alfa is a recombinant formulation of human a-galactosidase (AGAL), which is being used for the treatment of Fabry disease. Currently, this enzyme is manufactured by the Shire, a subsidiary of Takeda Pharmaceutical Company, with the brand name Replagal. To date, Replagal has received approval for marketing and production in Canda, the United Kingdom, and other parts of Europe.

Furthermore, according to the study published in JIMD, in 2019, Fabry disease is more prevalent in the population, which has been undergoing dialysis. Approximately 1.2% of the dialysis population has been reported with Fabry disease worldwide. Hence, the high prevalence of Fabry disease emerges the need for treatment, which is expected to boost up the enzyme replacement therapy market in the algasidase alfa segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global artificial disc market owing to initiatives taken by the government and other organizations related to rare diseases and its treatment. For instance, the National Institutes of Health awarded approximately USD 31 million in grants during 2019 to the 20 teams, including five new groups of scientists, clinicians, patients, families, and patients, to study a wide range of rare diseases. Additional USD 7 million has been provided to the data coordinating centers to support the research efforts. Furthermore, the National Center for Advancing Translational Sciences (NCATS), one of the centers of the National Institute of Health is solely dedicated to the treatment of patients with rare diseases. Also, the higher prevalence of rare diseases is expected to propel the enzyme replacement therapy in North America. According to the Genetic and Rare Diseases Information Center (GARD), at present, there are around 25 to 35 million people in the United States that suffer from rare diseases.

Competitive Landscape

Companies have been taking strategic initiatives related to enzyme replacement therapy to grow their presence in the market. For instance, recently Takeda exhibited its recent advances for lysosomal storage disorders at World Symposium in Orlando. Some of the key players who have been currently dominating the market are Genzyme Corporation, Pfizer Inc., Leadiant Biosciences, Inc., Biomarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited, Protalix Biotherapeutics, Amicus Therapeutics, and Johnson & Johnson Services Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Rare Diseases
    • 4.2.2 Increasing Government Initiatives for Rare Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Enzyme Type
    • 5.1.1 Agalsidase Alfa
    • 5.1.2 Agalsidase Beta
    • 5.1.3 Galsulfase
    • 5.1.4 Other Enzyme Types
  • 5.2 By Application
    • 5.2.1 Gaucher disease
    • 5.2.2 Pompe disease
    • 5.2.3 Fabry Disease
    • 5.2.4 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Amicus Therapeutics
    • 6.1.2 Biomarin Pharmaceutical Inc.
    • 6.1.3 Genzyme Corporation
    • 6.1.4 Johnson & Johnson
    • 6.1.5 Leadiant Biosciences Inc.
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Protalix Biotherapeutics
    • 6.1.8 Takeda Pharmaceutical Company Limited